4.6 Article

Anaphylaxis in an emergency setting - elicitors, therapy and incidence of severe allergic reactions

Journal

ALLERGY
Volume 67, Issue 11, Pages 1451-1456

Publisher

WILEY
DOI: 10.1111/all.12012

Keywords

adrenaline; anaphylaxis; emergency; treatment protocol

Funding

  1. Allergopharma
  2. ALK-Abello
  3. Meda

Ask authors/readers for more resources

Background Anaphylaxis is a severe potentially life-threatening hypersensitivity reaction with an estimated lifetime prevalence of 0.52.0%. The prevalence and incidence of anaphylactic reactions in Germany are unknown. We therefore assessed anaphylactic patients seen by emergency physicians in the Berlin area covering 4million people. Methods A standardised questionnaire was filled from 2008 to 2010 by the emergency physicians. Results A total of 333 cases of anaphylaxis were reported. 295 of these met the inclusion criteria for severity and were analysed. 13.9% (n=41) were reactions with respiratory symptoms, 25.4% (n=75) with cardiovascular, and in 60.7% (n=179) of cases, respiratory and cardiovascular symptoms were reported. Two reactions were fatal. The most common elicitors were food products (32.2%), drugs (29.2%) and insect venom (19.3%). The most frequently given drugs were corticoids and antihistamines, but not adrenaline. For 2008, the calculated incidence was 4.5 per 100000. Conclusions Our data show that food products are frequent elicitors of severe allergic reactions in the general population including children and adults. It unravels a strong underuse of adrenaline by emergency physicians, not reflecting treatment protocols according to the current guidelines. As data obtained from allergists reveal a different rank order of elicitors, this study suggests that food-allergic adult patients may present a risk population and should receive more attention by allergists.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Letter Allergy

Immune cell profiling reveals natural killer and T cell subpopulations to be associated with atopic dermatitis severity

Margitta Worm, Valerie Glatzel, Sabine Baumgart, Henrik E. Mei, Till Soerensen, Andreas Gruetzkau, Guido Heine

CLINICAL AND EXPERIMENTAL ALLERGY (2023)

Editorial Material Allergy

Patch testing shellac in consecutive patients-Data of the Information Network of Departments of Dermatology (IVDK) 2021

Steffen Schubert, Margitta Worm, Heinrich Dickel, Nicola Wagner, Richard Brans, Claudia Schroder-Kraft, Andrea Bauer, Andre Koch, Johannes Geier

CONTACT DERMATITIS (2023)

Review Allergy

Lack of Harmonized Adherence Criteria in Allergen Immunotherapy Prevents Comparison of Dosing and Application Strategies: A Scoping Review

Caroline Beutner, Jochen Schmitt, Margitta Worm, Martin Wagenmann, Christian Albus, Timo Buhl

Summary: Allergen immunotherapy (AIT) involves gradually increasing the dose of allergen extract until immunologic tolerance is achieved. Adherence to AIT is crucial for long-term success, but measuring adherence and persistence rates has been inconsistent. The development of standardized tools and parameters for measuring adherence in AIT is necessary. Additionally, exploring methods from adherence research in other chronic diseases could help improve outcomes in AIT.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE (2023)

Article Dermatology

Itching in Atopic Dermatitis: Patient- and Physician-reported Outcomes in the German Atopic Dermatitis Registry TREATgermany

Elke Weisshaar, Philipp Bentz, Christian Apfelbacher, Eva Haufe, Luise Heinrich, Annice Heratizadeh, Susanne Abraham, Inken Harder, Andreas Kleinheinz, Andreas Wollenberg, Knut Schaekel, Franca Wiemers, Julia Ertner, Matthias Augustin, Julia Wildberger, Ralph von Kiedrowski, Margitta Worm, Alexander Zink, Isaak Effendy, Andrea Asmussen, Mario Pawlak, Michael Sticherling, Melanie Hilgers, Christiane Handrick, Sven Quist, Beate Schwarz, Magnus Bell, Petra Staubach-Renz, Sung-Hei Hong-Weldemann, Bernhard Homey, Jens-Joachim Bruecher, Stephan Weidinger, Thomas Werfel, Jochen Schmitt

Summary: TREATgermany is a disease registry that investigates the severity, symptoms, treatment, and quality of life in patients with moderate to severe atopic dermatitis. The results show that 97.2% of patients experienced itch, and the severity of itch is correlated with the patient's self-reported disease severity.

ACTA DERMATO-VENEREOLOGICA (2023)

Article Allergy

Different phenotypes of drug-induced anaphylaxis-Data from the European Anaphylaxis Registry

Theresa Hanschmann, Wojciech Francuzik, Sabine Doelle-Bierke, Kathrin Scherer Hofmeier, Linus Grabenhenrich, Franziska Rueff, Jean-Marie Renaudin, Claudia Pfoehler, Regina Treudler, M. Beatrice Bilo, Roland Lang, Luis Felipe Ensina, George Christoff, Victoria Cardona, Nicola Wagner, Norbert Reider, Sabine Mueller, Heinrich Dickel, Margitta Worm

Summary: This study analyzes a large dataset on drug induced anaphylaxis and provides insights into its causes, risk factors, symptoms, and treatment. Drugs, particularly analgesics and antibiotics, are found to be the third most common cause of anaphylactic reactions. Female gender and older age are identified as relevant risk factors, while children are less affected by drug induced anaphylaxis.

ALLERGY (2023)

Biographical-Item Allergy

Obituary: Jorg Kleine-Tebbe

Stephanie Dramburg, Susanne Lau, Paolo Matricardi, Margitta Worm, Cezmi A. Akdis, Claus Bachert, Bruce Bochner, Stephen Durham, Johannes Ring, Heimo Breiteneder, Rudolf Valenta, Claudia Traidl-Hoffman

ALLERGY (2023)

Letter Dermatology

Itching and treatments in atopic dermatitis (AD): results from the German AD registry TREATgermany

Elke Weisshaar, Philipp Bentz, Eva Haufe, Luise Heinrich, Christian Apfelbacher, Annice Heratizadeh, Susanne Abraham, Inken Harder, Andreas Kleinheinz, Andreas Wollenberg, Knut Schaekel, Franca Wiemers, Konstantin Ertner, Matthias Augustin, Julia Wildberger, Ralph von Kiedrowski, Margitta Worm, Alexander Zink, Isaak Effendy, Andrea Asmussen, Mario Pawlak, Michael Sticherling, Melanie Hilgers, Christiane Handrick, Sven Quist, Beate Schwarz, Magnus Bell, Petra Staubach-Renz, Su-Hei Hong-Weldemann, Bernhard Homey, Jens Bruecher, Stephan Weidinger, Thomas Werfel, Jochen Schmitt

BRITISH JOURNAL OF DERMATOLOGY (2023)

Review Allergy

Health-related quality of life in food and venom induced anaphylaxis and role of influencing factors

Veronika Hoefer, Matteo Martini, Sabine Doelle-Bierke, Margitta Worm, Maria Beatrice Bilo

Summary: The impact on health-related quality of life (HRQL) is crucial for patients with allergies and anaphylaxis. This narrative review focuses on HRQL in allergic patients with food and venom allergies, which are the most common triggers for severe and life-threatening reactions. The review highlights the availability of standardized assessment tools for measuring HRQL in these patients and the various factors that can influence HRQL, including sociodemographic data and external factors. The review also emphasizes the importance of considering lifestyle factors and measuring individual changes in HRQL during specific immunotherapy.

CLINICAL AND EXPERIMENTAL ALLERGY (2023)

Review Allergy

Rhinitis associated with asthma is distinct from rhinitis alone: The ARIA-MeDALL hypothesis

J. Bousquet, E. Melen, T. Haahtela, G. H. Koppelman, A. Togias, R. Valenta, C. A. Akdis, W. Czarlewski, M. Rothenberg, A. Valiulis, M. Wickman, M. Akdis, D. Aguilar, A. Bedbrook, C. Bindslev-Jensen, S. Bosnic-Anticevich, L. P. Boulet, C. E. Brightling, L. Brussino, E. Burte, M. Bustamante, G. W. Canonica, L. Cecchi, J. C. Celedon, C. Chaves Loureiro, E. Costa, A. A. Cruz, M. Erhola, B. Gemicioglu, W. J. Fokkens, J. Garcia-Aymerich, S. Guerra, J. Heinrich, J. C. Ivancevich, T. Keil, L. Klimek, P. Kuna, M. Kupczyk, V. Kvedariene, D. E. Larenas-Linnemann, N. Lemonnier, K. C. Lodrup Carlsen, R. Louis, M. Makela, M. Makris, M. Maurer, I. Momas, M. Morais-Almeida, J. Mullol, R. N. Naclerio, K. Nadeau, R. Nadif, M. Niedoszytko, Y. Okamoto, M. Ollert, N. G. Papadopoulos, G. Passalacqua, V. Patella, R. Pawankar, N. Pham-Thi, O. Pfaar, F. S. Regateiro, J. Ring, P. W. Rouadi, B. Samolinski, J. Sastre, M. Savoure, N. Scichilone, M. H. Shamji, A. Sheikh, V. Siroux, B. Sousa-Pinto, M. Standl, J. Sunyer, L. Taborda-Barata, S. Toppila-Salmi, M. J. Torres, I. Tsiligianni, E. Valovirta, O. Vandenplas, M. T. Ventura, S. Weiss, A. Yorgancioglu, L. Zhang, A. H. Abdul Latiff, W. Aberer, I. Agache, M. Al-Ahmad, I. Alobid, I. J. Ansotegui, S. H. Arshad, E. Asayag, C. Barbara, A. Baharudin, L. Battur, K. S. Bennoor, E. C. Berghea, K. C. Bergmann, D. Bernstein, M. Bewick, H. Blain, M. Bonini, F. Braido, R. Buhl, R. S. Bumbacea, A. Bush, M. Calderon, M. Calvo-Gil, P. Camargos, L. Caraballo, V. Cardona, W. Carr, P. Carreiro-Martins, T. Casale, A. M. Cepeda Sarabia, R. Chandrasekharan, D. Charpin, Y. Z. Chen, I. Cherrez-Ojeda, T. Chivato, E. Chkhartishvili, G. Christoff, D. K. Chu, C. Cingi, J. Correia de Sousa, C. Corrigan, A. Custovic, G. D'Amato, S. Del Giacco, F. De Blay, P. Devillier, A. Didier, M. do Ceu Teixeira, D. Dokic, H. Douagui, M. Doulaptsi, S. Durham, M. Dykewicz, T. Eiwegger, Z. A. El-Sayed, R. Emuzyte, A. Fiocchi, N. Fyhrquist, R. M. Gomez, M. Gotua, M. A. Guzman, J. Hagemann, S. Hamamah, S. Halken, D. M. G. Halpin, M. Hofmann, E. Hossny, M. Hrubisko, C. Irani, Z. Ispayeva, E. Jares, T. Jartti, E. Jassem, K. Julge, J. Just, M. Jutel, I. Kaidashev, O. Kalayci, A. F. Kalyoncu, P. Kardas, B. Kirenga, H. Kraxner, I. Kull, M. Kulus, S. La Grutta, S. Lau, L. Le Tuyet Thi, M. Levin, B. Lipworth, O. Lourenco, B. Mahboub, E. Martinez-Infante, P. Matricardi, N. Miculinic, N. Migueres, F. Mihaltan, Y. Mohammad, M. Moniuszko, S. Montefort, H. Neffen, K. Nekam, E. Nunes, D. Nyembue Tshipukane, R. O'Hehir, I. Ogulur, K. Ohta, K. Okubo, S. Ouedraogo, H. Olze, I. Pali-Schoell, O. Palomares, K. Palosuo, C. Panaitescu, P. Panzner, H. S. Park, C. Pitsios, D. Plavec, T. A. Popov, F. Puggioni, S. Quirce, M. Recto, M. S. Repka-Ramirez, C. Robalo Cordeiro, N. Roche, M. Rodriguez-Gonzalez, J. Romantowski, N. Rosario Filho, M. Rottem, H. Sagara, F. S. Serpa, Z. Sayah, S. Scheire, P. Schmid-Grendelmeier, J. C. Sisul, D. Sole, M. Soto-Martinez, M. Sova, A. Sperl, O. Spranger, R. Stelmach, C. Suppli Ulrik, M. Thomas, T. To, A. Todo-Bom, P. V. Tomazic, M. Urrutia-Pereira, M. Valentin-Rostan, E. Van Ganse, M. van Hage, T. Vasankari, P. Vichyanond, G. Viegi, D. Wallace, D. Y. Wang, S. Williams, M. Worm, P. Yiallouros, O. Yusuf, F. Zaitoun, M. Zernotti, M. Zidarn, J. Zuberbier, J. A. Fonseca, T. Zuberbier, J. M. Anto

Summary: Asthma, rhinitis, and atopic dermatitis are interrelated clinical phenotypes. The concept of one-airway-one-disease, which simplifies the links between upper and lower airway allergic diseases, needs to be reassessed based on new data.

ALLERGY (2023)

Article Allergy

Patch testing hydroperoxides of limonene and linalool in consecutive patients-Results of the IVDK 2018-2020

Steffen Schubert, Johannes Geier, Richard Brans, Annice Heratizadeh, Birger Kraenke, Axel Schnuch, Andrea Bauer, Heinrich Dickel, Timo Buhl, Dieter Vieluf, Nicola Wagner, Margitta Worm

Summary: Positive patch test reactions to Limonene hydroperoxides (Lim-OOHs) and Linalool hydroperoxides (Lin-OOHs) were frequent in consecutive patients, but most of the reactions were weak, doubtful, or irritant in nature. Patients with irritant reactions to sodium lauryl sulphate (SLS) were more likely to react to Lim-OOHs and Lin-OOHs. It is recommended to chemically monitor test preparations to reduce irritancy and interpret patch test results carefully.

CONTACT DERMATITIS (2023)

Letter Dermatology

IL-1α/β and IL-18 profiles and their impact on claudin-1, loricrin and filaggrin expression in patients with atopic dermatitis

M. Michaelidou, D. Redhu, V. Kumari, M. Babina, M. Worm

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2023)

Letter Dermatology

The Janus kinase 1 inhibitor abrocitinib for the treatment of oral lichen planus

Farzan Solimani, Alberto Mesas-Fernandez, Amrei Dilling, Alexander Nast, Franz J. Hilke, Franziska C. Ghoreschi, Margitta Worm, Kamran Ghoreschi, Katharina Meier

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2023)

Article Medicine, General & Internal

Two Phase 3 Trials of Lebrikizumab for Moderate-to-Severe Atopic Dermatitis

Jonathan I. Silverberg, Emma Guttman-Yassky, Diamant Thaci, Alan D. Irvine, Linda Stein Gold, Andrew Blauvelt, Eric L. Simpson, Chia-Yu Chu, Zhuqing Liu, Renata Gontijo Lima, Sreekumar G. Pillai, Julien Seneschal

Summary: Two 52-week trials showed that treatment with lebrikizumab was effective in improving skin condition and reducing itch severity in patients with moderate-to-severe atopic dermatitis. The incidence of adverse events was generally mild to moderate and did not lead to trial discontinuation.

NEW ENGLAND JOURNAL OF MEDICINE (2023)

Review Allergy

Health-Related Quality of Life and Mental Health in Drug Hypersensitivity Reactions and Drug-Induced Anaphylaxis: A Systematic Review and Meta-Analysis

Matteo Martini, Mariateresa Di Taranto, Veronika Hoefer, Margitta Worm, Maria Beatrice Bilo

Summary: This study evaluated the prevalence, severity, and risk factors of health-related quality of life (HRQoL) and mental health in patients with drug hypersensitivity reactions (DHRs), and found that these patients commonly experience depression and anxiety, and have significantly impaired HRQoL, especially in the case of drug-induced anaphylaxis.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE (2023)

Article Medicine, General & Internal

Two Phase 3 Trials of Lebrikizumab for Moderate-to-Severe Atopic Dermatitis

Jonathan I. Silverberg, Emma Guttman-Yassky, Diamant Thaci, Alan D. Irvine, Linda Stein Gold, Andrew Blauvelt, Eric L. Simpson, Chia-Yu Chu, Zhuqing Liu, Renata Gontijo Lima, Sreekumar G. Pillai, Julien Seneschal

Summary: The study shows that lebrikizumab is effective in treating moderate-to-severe atopic dermatitis in both adolescents and adults, with significant improvements in skin lesions and reduction of itch symptoms during the 16-week induction period.

NEW ENGLAND JOURNAL OF MEDICINE (2023)

No Data Available